RoosterBio
roosterbio.com
Regenerative Medicine
Bioprocessing
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$17.2M
3 rounds on record
Latest round
$12M
Venture round · Mar 2024 · 2 yr ago
Team
49
US Form 5500 (plan participants) · Dec 2025 · +2% in a year
Backers
1
Vanedge Capital
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 7
Partnership RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions · morningstar.com
Apr 7
Partnership RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China · morningstar.com
Mar 8, 2024
Raised a round Venture round $12M · SEC Form D
Sep 6, 2019
Launched RoosterBio Launches the Only Umbilical Cord hMSC System in the World Designed for Cell Therapy Product Development · markets.businessinsider.com
Dec 9, 2018
Partnership RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell… · markets.businessinsider.com
Jan 27, 2017
Took on debt financing $1.3M · SEC Form D
Nov 23, 2016
Raised a round Venture round $5.2M · SEC Form D
2013
Founded
Tractionpublic signals, read monthly
Web presence
top 3%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2024 | $12M | — | SEC Form D |
| Debt Financing | Jan 2017 | $1.3M | — | SEC Form D |
| Venture round | Nov 2016 | $5.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | RoosterBio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Margot ConnorExecutive Officer, DirectorSEC Form D
Jon RowleyDirectorSEC Form D
Timothy KellyExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable…
Unlocking Cellular Innovation. The first-choice bioprocessing and scale-up partner for the sustainable bioeconomy.
Organ-on-a-chip supplier of the 1st human-derived hydrogel for 2D & 3D cell culture. Our fat-on-a-chip platform is a more accurate way to…
BioLink is a Chinese supplier of core equipment and consumables for biopharmaceutical and life science customers, covering cell culture…
InSpek delivers real-time, in-line multiparameter visibility for bioprocessing, chemical and pharmaceutical manufacturing. Turn…
We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Vanedge CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
How Professor Ken Witwer's Lab at Johns Hopkins Is Revising Assumptions About Extracellular Vesicles
An Interview with Dr. Kenneth Witwer, PhD Associate Professor of Molecular and Comparative Pathobiology Johns Hopkins University School of Medicine Progress in cell and gene therapy is made by people who work across disciplines and build across constraint
Read more
Report
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanc
Read more
Report
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
/PRNewswire/ -- Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC)...
Read more
Report
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
Read more
Report
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers
RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge
Read more
Report
What Does It Take to Engineer MSCs into a Scalable Immunotherapy?
An Interview with Dr. Moutih Rafei Associate Professor, Department of Pharmacology and Physiology Université de Montréal Progress in cell and gene therapy is made by people who work across disciplines and build across constraints. RoosterBio's AMA (Ask Me
Read more
Report
How DSP Decisions Shape Scale, Yield, & Cost of Goods in Exosome Preparation
Many EV therapeutics will never reach patients - not because the biology fails, but because the manufacturing economics miss the mark. RoosterBio builds downstream processing (DSP) platforms designed from day one for commercial scale, using scalable unit
Read more
Report
RoosterBio's New Passages to San Juan (ISEV), Dublin (ISCT), & Montréal (ISSCR) at 2026 Conferences
RoosterBio presents seven posters across ISEV 2026 (San Juan), ISCT 2026 (Dublin), and ISSCR 2026 (Montréal), covering scalable MSC-EV upstream production, GMP-compatible downstream processing, and orthogonal potency analytics including CD73 characterizat
Read more
Report
Critical Process Parameters in Primary Cell Manufacturing: Why & How They Matter for MSCs or Human Dermal Fibroblasts
Revisiting "Identify & Define Your Cell Therapy's Biomanufacturing Approach for Critical Process Parameters (CPPs)" by Josephine Lembong, PhD 1 One of the most recycled mantras in cell and gene therapy manufacturing goes like this: "The process is the pro
Read more
Report
Show more news
People
Margot Connor
Executive Officer, Director
Jon Rowley
Director
Timothy Kelly
Executive Officer, Director
Robert Carlson
Director
Rob Carlson
Director
Daniella Kranjac
Director
Robert Preti
Director
Susan Riley
Director
Martin Westberg
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Frederick
United States
HQ
50-200 est. staff